Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) FCF Margin (2016 - 2025)

Northwest Biotherapeutics' FCF Margin history spans 16 years, with the latest figure at 2331.7% for Q4 2025.

  • Quarterly results put FCF Margin at 2331.7% for Q4 2025, up 643843.0% from a year ago — trailing twelve months through Dec 2025 was 3357.55% (up 84151.0% YoY), and the annual figure for FY2025 was 3357.55%, up 84151.0%.
  • FCF Margin for Q4 2025 was 2331.7% at Northwest Biotherapeutics, up from 7047.5% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1428.64% in Q1 2023 to a low of 8770.13% in Q4 2024.
  • The 5-year median for FCF Margin is 3278.04% (2024), against an average of 4104.41%.
  • The sharpest move saw FCF Margin surged 37665505bps in 2021, then plummeted -518568bps in 2022.
  • Year by year, FCF Margin stood at 2772.57% in 2021, then skyrocketed by 33bps to 1844.05% in 2022, then plummeted by -112bps to 3904.72% in 2023, then tumbled by -125bps to 8770.13% in 2024, then surged by 73bps to 2331.7% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 2331.7%, 7047.5%, and 5337.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.